These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 8523339

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
    Hurst S, Kallan MJ, Wolfe FJ, Fries JF, Albert DA.
    J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
    [Abstract] [Full Text] [Related]

  • 3. How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.
    Klinkhoff AV, Teufel A.
    J Rheumatol; 1995 Sep; 22(9):1657-9. PubMed ID: 8523340
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Characterization of patients with arthritis referred for gold therapy in the era of biologics.
    Cheung JM, Scarsbrook D, Klinkhoff AV.
    J Rheumatol; 2012 Apr; 39(4):716-9. PubMed ID: 22337247
    [Abstract] [Full Text] [Related]

  • 6. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders.
    Thurlings RM, Vos K, Gerlag DM, Tak PP.
    Arthritis Rheum; 2008 Dec; 58(12):3657-64. PubMed ID: 19035505
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study.
    Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J, METGO Study Group.
    Arthritis Rheum; 2005 May; 52(5):1360-70. PubMed ID: 15880810
    [Abstract] [Full Text] [Related]

  • 9. Safety of self-injection of gold and methotrexate.
    Arthur AB, Klinkhoff AV, Teufel A.
    J Rheumatol; 1999 Feb; 26(2):302-5. PubMed ID: 9972962
    [Abstract] [Full Text] [Related]

  • 10. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases.
    Ujfalussy I, Koó E, Seszták M, Gergely P.
    Z Rheumatol; 2003 Apr; 62(2):155-60. PubMed ID: 12721703
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [Abstract] [Full Text] [Related]

  • 17. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.
    Silverman E, Spiegel L, Hawkins D, Petty R, Goldsmith D, Schanberg L, Duffy C, Howard P, Strand V.
    Arthritis Rheum; 2005 Feb; 52(2):554-62. PubMed ID: 15693001
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
    Galindo-Rodriguez G, Aviña-Zubieta JA, Russell AS, Suarez-Almazor ME.
    J Rheumatol; 1999 Nov; 26(11):2337-43. PubMed ID: 10555887
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.